Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
SAN DIEGO , June 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors.  Ms. Jarrett has over 20 years of experience as a senior executive and finance professional in the life sciences industry. 
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th
SAN DIEGO , June 1, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:30am EDT . The conference will take place June
View HTML
Toggle Summary Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
- Lewis Rubin, M.D. and Vallerie McLaughlin, M.D. to Present
View HTML
Toggle Summary Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
SAN DIEGO , May 16, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH),
View HTML
Toggle Summary Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , April 21, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000 shares of its common stock, including 9,000,000 shares sold pursuant to the full exercise of an option
View HTML
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 60,000,000 shares of its common stock, offered at a price to the public of $1.15 per share.  The gross proceeds from the offering are expected to
View HTML
Toggle Summary Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters a 30‑day option to
View HTML
Toggle Summary Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
SAN DIEGO , March 27, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi , the Company's President and Chief Executive Officer, will present
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer
SAN DIEGO , March 20, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced the appointment of Dr. Preston Klassen , M.D., M.H.S.
View HTML